MedTrace Logo

Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer

NCT02247037 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2020-07-07

No results posted yet for this study

Summary

This study will determine if patient-derived tumor xenograft (PDX) mouse models can serve as a reliable model for treatment response for individual patients with triple negative breast cancer. The collection of patient tumor tissue will also provide insight into the mechanisms of therapeutic resistance for those individuals. Ultimately, this study will enhance our understanding of the genomic basis for treatment response for triple negative cancer on an individual basis, while having the potential to suggest new therapeutic options for high-risk triple negative breast cancer patients with residual disease post neoadjuvant.

Conditions

Interventions

OTHER

Chemotherapy

Patients are treated with neoadjuvant chemotherapy as according to the standard of care guidelines. Patients with metastatic disease are treated according to standard of care guidelines.

Sponsors & Collaborators

Principal Investigators

  • Hanna Yoko Irie, MD, PhD · Dubin Breast Center of The Tisch Cancer Institute at Mount Sinai

  • Elisa Port, MD · Dubin Breast Center of The Tisch Cancer Institute at Mount Sinai

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2019-01-22
Completion
2019-01-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02247037 on ClinicalTrials.gov